"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","data_processing","platform_id","contact_name","contact_email","contact_department","contact_institute","contact_address","contact_city","contact_zip/postal_code","contact_country","contact_web_link","supplementary_file","data_row_count","relation"
"GSM712573","colorectal cancer sample AUS2_003_p348 [exon-level]","GSM712573","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-L","disease_specific_survival_event: 1","disease_specific_survival_years: 2.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712573/GSM712573_AUS2_003_p348_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712398 (gene-level)"
"GSM712574","colorectal cancer sample AUS2_010_p1622 [exon-level]","GSM712574","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 5.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712574/GSM712574_AUS2_010_p1622_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712399 (gene-level)"
"GSM712575","colorectal cancer sample AUS2_011_p423 [exon-level]","GSM712575","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712575/GSM712575_AUS2_011_p423_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712400 (gene-level)"
"GSM712576","colorectal cancer sample AUS2_012_p336 [exon-level]","GSM712576","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 4.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712576/GSM712576_AUS2_012_p336_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712401 (gene-level)"
"GSM712577","colorectal cancer sample AUS2_013_p874 [exon-level]","GSM712577","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712577/GSM712577_AUS2_013_p874_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712402 (gene-level)"
"GSM712578","colorectal cancer sample AUS2_017_p296 [exon-level]","GSM712578","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712578/GSM712578_AUS2_017_p296_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712403 (gene-level)"
"GSM712579","colorectal cancer sample AUS2_018_p1355 [exon-level]","GSM712579","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712579/GSM712579_AUS2_018_p1355_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712404 (gene-level)"
"GSM712580","colorectal cancer sample AUS2_019_p312 [exon-level]","GSM712580","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 4.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712580/GSM712580_AUS2_019_p312_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712405 (gene-level)"
"GSM712581","colorectal cancer sample AUS2_022_p452 [exon-level]","GSM712581","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 4.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712581/GSM712581_AUS2_022_p452_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712406 (gene-level)"
"GSM712582","colorectal cancer sample AUS2_024_p280 [exon-level]","GSM712582","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 4.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712582/GSM712582_AUS2_024_p280_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712407 (gene-level)"
"GSM712583","colorectal cancer sample AUS2_026_p473 [exon-level]","GSM712583","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712583/GSM712583_AUS2_026_p473_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712408 (gene-level)"
"GSM712584","colorectal cancer sample AUS2_027_p876 [exon-level]","GSM712584","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 0.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712584/GSM712584_AUS2_027_p876_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712409 (gene-level)"
"GSM712585","colorectal cancer sample AUS2_028_p256 [exon-level]","GSM712585","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712585/GSM712585_AUS2_028_p256_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712410 (gene-level)"
"GSM712586","colorectal cancer sample AUS2_029_p476 [exon-level]","GSM712586","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 4.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712586/GSM712586_AUS2_029_p476_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712411 (gene-level)"
"GSM712587","colorectal cancer sample AUS2_030_p340 [exon-level]","GSM712587","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 4.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712587/GSM712587_AUS2_030_p340_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712412 (gene-level)"
"GSM712588","colorectal cancer sample AUS2_031_p478 [exon-level]","GSM712588","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 1","disease_specific_survival_years: 3.4","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712588/GSM712588_AUS2_031_p478_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712413 (gene-level)"
"GSM712589","colorectal cancer sample AUS2_036_p504 [exon-level]","GSM712589","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.5","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712589/GSM712589_AUS2_036_p504_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712414 (gene-level)"
"GSM712590","colorectal cancer sample AUS2_037_p304 [exon-level]","GSM712590","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 4.5","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712590/GSM712590_AUS2_037_p304_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712415 (gene-level)"
"GSM712591","colorectal cancer sample AUS2_038_p249 [exon-level]","GSM712591","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.5","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712591/GSM712591_AUS2_038_p249_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712416 (gene-level)"
"GSM712592","colorectal cancer sample AUS2_041_p260 [exon-level]","GSM712592","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712592/GSM712592_AUS2_041_p260_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712417 (gene-level)"
"GSM712593","colorectal cancer sample AUS2_042_p506 [exon-level]","GSM712593","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-L","disease_specific_survival_event: 1","disease_specific_survival_years: 2.1","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712593/GSM712593_AUS2_042_p506_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712418 (gene-level)"
"GSM712594","colorectal cancer sample AUS2_043_p1327 [exon-level]","GSM712594","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 1","disease_specific_survival_years: 2.5","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712594/GSM712594_AUS2_043_p1327_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712419 (gene-level)"
"GSM712595","colorectal cancer sample AUS2_044_p268 [exon-level]","GSM712595","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 2.3","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712595/GSM712595_AUS2_044_p268_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712420 (gene-level)"
"GSM712596","colorectal cancer sample AUS2_048_p344 [exon-level]","GSM712596","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 1","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712596/GSM712596_AUS2_048_p344_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712421 (gene-level)"
"GSM712597","colorectal cancer sample AUS2_050_p533 [exon-level]","GSM712597","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.3","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712597/GSM712597_AUS2_050_p533_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712422 (gene-level)"
"GSM712598","colorectal cancer sample AUS2_051_p1596 [exon-level]","GSM712598","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712598/GSM712598_AUS2_051_p1596_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712423 (gene-level)"
"GSM712599","colorectal cancer sample AUS2_053_p328 [exon-level]","GSM712599","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 1","disease_specific_survival_years: 0.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712599/GSM712599_AUS2_053_p328_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712424 (gene-level)"
"GSM712600","colorectal cancer sample AUS2_054_p272 [exon-level]","GSM712600","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 1","disease_specific_survival_years: 1.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712600/GSM712600_AUS2_054_p272_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712425 (gene-level)"
"GSM712601","colorectal cancer sample AUS2_055_p536 [exon-level]","GSM712601","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712601/GSM712601_AUS2_055_p536_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712426 (gene-level)"
"GSM712602","colorectal cancer sample AUS2_058_p538 [exon-level]","GSM712602","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 0.5","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712602/GSM712602_AUS2_058_p538_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712427 (gene-level)"
"GSM712603","colorectal cancer sample AUS2_065_p551 [exon-level]","GSM712603","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712603/GSM712603_AUS2_065_p551_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712428 (gene-level)"
"GSM712604","colorectal cancer sample AUS2_068_p564 [exon-level]","GSM712604","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 4.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712604/GSM712604_AUS2_068_p564_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712429 (gene-level)"
"GSM712605","colorectal cancer sample AUS2_070_p566 [exon-level]","GSM712605","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 4.1","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712605/GSM712605_AUS2_070_p566_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712430 (gene-level)"
"GSM712606","colorectal cancer sample AUS2_072_p590 [exon-level]","GSM712606","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 4.1","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712606/GSM712606_AUS2_072_p590_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712431 (gene-level)"
"GSM712607","colorectal cancer sample AUS2_075_p595 [exon-level]","GSM712607","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 4.1","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712607/GSM712607_AUS2_075_p595_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712432 (gene-level)"
"GSM712608","colorectal cancer sample AUS2_084_p622 [exon-level]","GSM712608","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 4.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712608/GSM712608_AUS2_084_p622_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712433 (gene-level)"
"GSM712609","colorectal cancer sample AUS2_086_p624 [exon-level]","GSM712609","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712609/GSM712609_AUS2_086_p624_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712434 (gene-level)"
"GSM712610","colorectal cancer sample AUS2_089_p645 [exon-level]","GSM712610","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 1","disease_specific_survival_years: 2.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712610/GSM712610_AUS2_089_p645_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712435 (gene-level)"
"GSM712611","colorectal cancer sample AUS2_090_p646 [exon-level]","GSM712611","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712611/GSM712611_AUS2_090_p646_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712436 (gene-level)"
"GSM712612","colorectal cancer sample AUS2_091_p647 [exon-level]","GSM712612","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-L","disease_specific_survival_event: 0","disease_specific_survival_years: 3.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712612/GSM712612_AUS2_091_p647_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712437 (gene-level)"
"GSM712613","colorectal cancer sample AUS2_092_p648 [exon-level]","GSM712613","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712613/GSM712613_AUS2_092_p648_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712438 (gene-level)"
"GSM712614","colorectal cancer sample AUS2_093_p649 [exon-level]","GSM712614","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 1","disease_specific_survival_years: 1.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712614/GSM712614_AUS2_093_p649_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712439 (gene-level)"
"GSM712615","colorectal cancer sample AUS2_094_p640 [exon-level]","GSM712615","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712615/GSM712615_AUS2_094_p640_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712440 (gene-level)"
"GSM712616","colorectal cancer sample AUS2_096_p652 [exon-level]","GSM712616","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712616/GSM712616_AUS2_096_p652_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712441 (gene-level)"
"GSM712617","colorectal cancer sample AUS2_097_p643 [exon-level]","GSM712617","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712617/GSM712617_AUS2_097_p643_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712442 (gene-level)"
"GSM712618","colorectal cancer sample AUS2_098_p665 [exon-level]","GSM712618","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712618/GSM712618_AUS2_098_p665_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712443 (gene-level)"
"GSM712619","colorectal cancer sample AUS2_100_p668 [exon-level]","GSM712619","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712619/GSM712619_AUS2_100_p668_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712444 (gene-level)"
"GSM712620","colorectal cancer sample AUS2_114_p1356 [exon-level]","GSM712620","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712620/GSM712620_AUS2_114_p1356_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712445 (gene-level)"
"GSM712621","colorectal cancer sample AUS2_117_p906_2 [exon-level]","GSM712621","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712621/GSM712621_AUS2_117_p906_HuEx-1_0-st-v2_2.CEL.gz","284258","Alternative to: GSM712446 (gene-level)"
"GSM712622","colorectal cancer sample AUS2_118_p907 [exon-level]","GSM712622","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712622/GSM712622_AUS2_118_p907_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712447 (gene-level)"
"GSM712623","colorectal cancer sample AUS2_119_p927 [exon-level]","GSM712623","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712623/GSM712623_AUS2_119_p927_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712448 (gene-level)"
"GSM712624","colorectal cancer sample AUS2_123_p931 [exon-level]","GSM712624","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.7","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712624/GSM712624_AUS2_123_p931_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712449 (gene-level)"
"GSM712625","colorectal cancer sample AUS2_127_p914 [exon-level]","GSM712625","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.6","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712625/GSM712625_AUS2_127_p914_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712450 (gene-level)"
"GSM712626","colorectal cancer sample AUS2_129_p934 [exon-level]","GSM712626","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 1","disease_specific_survival_years: 2.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712626/GSM712626_AUS2_129_p934_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712451 (gene-level)"
"GSM712627","colorectal cancer sample AUS2_130_p935 [exon-level]","GSM712627","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.4","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712627/GSM712627_AUS2_130_p935_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712452 (gene-level)"
"GSM712628","colorectal cancer sample AUS2_134_p949 [exon-level]","GSM712628","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.4","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712628/GSM712628_AUS2_134_p949_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712453 (gene-level)"
"GSM712629","colorectal cancer sample AUS2_140_p954 [exon-level]","GSM712629","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.3","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712629/GSM712629_AUS2_140_p954_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712454 (gene-level)"
"GSM712630","colorectal cancer sample AUS2_144_p966 [exon-level]","GSM712630","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712630/GSM712630_AUS2_144_p966_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712455 (gene-level)"
"GSM712631","colorectal cancer sample AUS2_145_p977 [exon-level]","GSM712631","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712631/GSM712631_AUS2_145_p977_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712456 (gene-level)"
"GSM712632","colorectal cancer sample AUS2_147_p989 [exon-level]","GSM712632","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712632/GSM712632_AUS2_147_p989_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712457 (gene-level)"
"GSM712633","colorectal cancer sample AUS2_153_p993 [exon-level]","GSM712633","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.2","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712633/GSM712633_AUS2_153_p993_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712458 (gene-level)"
"GSM712634","colorectal cancer sample AUS2_158_p995 [exon-level]","GSM712634","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.1","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712634/GSM712634_AUS2_158_p995_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712459 (gene-level)"
"GSM712635","colorectal cancer sample AUS2_165_p1011 [exon-level]","GSM712635","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: MSI-H","disease_specific_survival_event: 0","disease_specific_survival_years: 3.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712635/GSM712635_AUS2_165_p1011_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712460 (gene-level)"
"GSM712636","colorectal cancer sample AUS2_167_p1013 [exon-level]","GSM712636","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712636/GSM712636_AUS2_167_p1013_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712461 (gene-level)"
"GSM712637","colorectal cancer sample AUS2_169_p1014 [exon-level]","GSM712637","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712637/GSM712637_AUS2_169_p1014_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712462 (gene-level)"
"GSM712638","colorectal cancer sample AUS2_171_p1015 [exon-level]","GSM712638","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: MSS","disease_specific_survival_event: 0","disease_specific_survival_years: 3.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712638/GSM712638_AUS2_171_p1015_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712463 (gene-level)"
"GSM712639","colorectal cancer sample AUS2_175_p1471 [exon-level]","GSM712639","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 3.0","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712639/GSM712639_AUS2_175_p1471_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712464 (gene-level)"
"GSM712640","colorectal cancer sample AUS2_177_p1569 [exon-level]","GSM712640","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712640/GSM712640_AUS2_177_p1569_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712465 (gene-level)"
"GSM712641","colorectal cancer sample AUS2_182_p1478 [exon-level]","GSM712641","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712641/GSM712641_AUS2_182_p1478_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712466 (gene-level)"
"GSM712642","colorectal cancer sample AUS2_183_p1575 [exon-level]","GSM712642","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712642/GSM712642_AUS2_183_p1575_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712467 (gene-level)"
"GSM712643","colorectal cancer sample AUS2_184_p1576 [exon-level]","GSM712643","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712643/GSM712643_AUS2_184_p1576_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712468 (gene-level)"
"GSM712644","colorectal cancer sample AUS2_185_p1577 [exon-level]","GSM712644","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712644/GSM712644_AUS2_185_p1577_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712469 (gene-level)"
"GSM712645","colorectal cancer sample AUS2_186_p1482 [exon-level]","GSM712645","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.9","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712645/GSM712645_AUS2_186_p1482_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712470 (gene-level)"
"GSM712646","colorectal cancer sample AUS2_187_p1579 [exon-level]","GSM712646","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712646/GSM712646_AUS2_187_p1579_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712471 (gene-level)"
"GSM712647","colorectal cancer sample AUS2_190_p1486 [exon-level]","GSM712647","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 2","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712647/GSM712647_AUS2_190_p1486_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712472 (gene-level)"
"GSM712648","colorectal cancer sample AUS2_197_p1588 [exon-level]","GSM712648","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712648/GSM712648_AUS2_197_p1588_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712473 (gene-level)"
"GSM712649","colorectal cancer sample AUS2_200_p1591 [exon-level]","GSM712649","Public on May 19 2011","Apr 21 2011","May 19 2011","RNA","1","Colorectal cancer patient","Homo sapiens","tissue: colorectal cancer biopsy","tumor stage: 3","msi-status: NA","disease_specific_survival_event: 0","disease_specific_survival_years: 2.8","total RNA","For the colorectal cancer samples, total RNA was isolated from <30 mg tissue biopsies using the AllPrep DNA/RNA Mini kit (Qiagen), according to the manufacturer's protocol. For the normal colon mucosa samples, total RNA was isolated from <100 mg tissue biopsies using the Ambion RiboPure kit (Life Technologies), according to the manufacturer's protocol.","biotin","Single-stranded cDNA was generated from the amplified cRNA with the WT cDNA Synthesis Kit (Affymetrix) and then fragmented and labeled with the WT Terminal Labeling Kit (Affymetrix).","9606","Samples were hybridized with GeneChip Human Exon 1.0 ST Arrays (Affymetrix)","Array scanning was performed according to the manufacturer's instruction (Affymetrix)","Alternative splicing score resulting from running the FIRMA algorithm implemented with an R code in the aroma.affymetrix Bioconductor package","For analysis at the exon level, raw data were processed (using a custom-made cdf-file; HuEx-1_0-st-v2,coreR3,A20071112,EP.cdf) and analyzed for alternative splicing with the FIRMA algorithm (aroma.affymetrix). For gene-level analysis, raw data were processed with the RMA procedure using Expression Console (Affymetrix; gene-core analysis).","GPL11028","Anita,,Sveen","anita.sveen@rr-research.no","Department of Cancer Prevention, Institute for Cancer Research","Oslo University Hospital, The Norwegian Radium Hospital","P.O.Box 4953, Nydalen","Oslo","NO-0424","Norway","http://www.ous-research.no/cancerprevention/","ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM712nnn/GSM712649/GSM712649_AUS2_200_p1591_HuEx-1_0-st-v2_.CEL.gz","284258","Alternative to: GSM712474 (gene-level)"
